Haleon PLC

Haleon PLC’s board shift—Sir Dave Lewis steps down, Vindi Banga becomes chair—brings new focus on value‑based pricing, patent‑cliff strategy and M&A to safeguard growth and shareholder value.

Haleon PLC releases unaudited Q3 2025 results, meeting SEBI LODR requirements but offering only high‑level figures, so investors await detailed earnings commentary for full insight.

Haleon PLC’s Q3 shows modest revenue growth but missed earnings targets; key insights reveal how Sensodyne’s 7 % sales lift, patent strategy, and digital expansion shape the company’s long‑term outlook.

Haleon PLC, a leading consumer-healthcare company, has formed a strategic partnership with Salesforce to deploy AI-driven CRM solutions and enhance engagement with pharmacies and healthcare professionals worldwide.

Haleon PLC’s share price has remained relatively stable despite market volatility, thanks to strategic share repurchases and a growing global presence through its partnership with Wellnex Life.

Haleon PLC, a leading consumer-health firm, faces a mix of opportunities and challenges in the global healthcare market, including growth in OTC sales, reimbursement pressures, and operational efficiencies, which will impact its valuation and invest…

Haleon PLC’s stock price has declined to a 52-week low, but analysts remain optimistic about the company’s long-term prospects due to its strong brand portfolio and commitment to innovation.

Haleon’s share price has experienced a notable fluctuation, dropping from its 52-week high but surpassing its 52-week low, influenced by market sentiment, economic indicators, and industry trends.

Haleon’s share price has been highly volatile over the past year, fluctuating from a 52-week high of 419.5 GBP to a 52-week low of 346.1 GBP.

Haleon PLC’s stock price has surged due to improved UK inflation data and a more optimistic economic outlook, driving renewed confidence in the company’s prospects.